The propensity score matched EVERBIO trial showed similar risk of death, MI and TVR in BES compared to EES during a 2-year follow-up [11].
The randomized COMPARE II trial enrolling 2,707 patients, confirmed the BES safety but no differences were observed in clinical endpoints at 2-year follow-up when compared to EES [12].